217 related articles for article (PubMed ID: 10849529)
1. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial.
Yanovich S; Mitsky P; Cornetta K; Maziarz RT; Rosenfeld C; Krause DS; Lotz JP; Bitran JD; Williams S; Preti R; Somlo G; Burtness B; Mills B
Bone Marrow Transplant; 2000 Jun; 25(11):1165-74. PubMed ID: 10849529
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
3. Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients.
Richel DJ; Johnsen HE; Canon J; Guillaume T; Schaafsma MR; Schenkeveld C; Hansen SW; McNiece I; Gringeri AJ; Briddell R; Ewen C; Davies R; Freeman J; Miltenyi S; Symann M
Bone Marrow Transplant; 2000 Feb; 25(3):243-9. PubMed ID: 10673694
[TBL] [Abstract][Full Text] [Related]
4. Enrichment of peripheral blood CD34+ cells for transplantation using a fully automated immunomagnetic cell selection system and a novel octapeptide releasing agent.
Marolleau JP; Dal Cortivo L; Mills B; Fermand JP; Miclea JM; Lotz JP; Gisselbrecht C; Benbunan M
Bone Marrow Transplant; 1999 Apr; 23(8):819-26. PubMed ID: 10231145
[TBL] [Abstract][Full Text] [Related]
5. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
Kasow KA; Sims-Poston L; Eldridge P; Hale GA
Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
[TBL] [Abstract][Full Text] [Related]
6. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
7. [Effect of immunomagnetic selection in purging autologous peripheral blood progenitor cell of breast cancer patients].
Han X; Shi Y; Zhang W
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):203-6. PubMed ID: 11953162
[TBL] [Abstract][Full Text] [Related]
8. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
[TBL] [Abstract][Full Text] [Related]
9. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
[TBL] [Abstract][Full Text] [Related]
10. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
12. Clearance kinetics of CD34+ cells from peripheral blood: an independent predictor of hematologic recovery after high-dose chemotherapy and hematopoietic stem cell transplantation.
D'Hondt L; Wuu J; André M; Lerberghe C; Guillaume T; Feyens AM; Humblet Y; Dromelet A; Chatelain B; Longueville J; Stewart F; D'Hondt V; Symann M
Bone Marrow Transplant; 1999 Sep; 24(5):483-9. PubMed ID: 10482931
[TBL] [Abstract][Full Text] [Related]
13. [High-dose therapy of cancer with CD34 positive cells as stem cell support].
Kvalheim G; Pharo A; Holte H; Jakobsen E; Erikstein B; Kvaløy S; Beiske K; Nesland JM; Smeland EB
Tidsskr Nor Laegeforen; 1996 Sep; 116(21):2542-6. PubMed ID: 8928121
[TBL] [Abstract][Full Text] [Related]
14. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.
Dyson PG; Horvath N; Joshua D; Barrow L; Van Holst NG; Brown R; Gibson J; To LB
Bone Marrow Transplant; 2000 Jun; 25(11):1175-84. PubMed ID: 10849530
[TBL] [Abstract][Full Text] [Related]
15. Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system.
Rowley SD; Loken M; Radich J; Kunkle LA; Mills BJ; Gooley T; Holmberg L; McSweeney P; Beach K; MacLeod B; Appelbaum F; Bensinger WI
Bone Marrow Transplant; 1998 Jun; 21(12):1253-62. PubMed ID: 9674860
[TBL] [Abstract][Full Text] [Related]
16. Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma.
Handgretinger R; Lang P; Ihm K; Schumm M; Geiselhart A; Koscielniak E; Hero B; Klingebiel T; Niethammer D
Bone Marrow Transplant; 2002 May; 29(9):731-6. PubMed ID: 12040469
[TBL] [Abstract][Full Text] [Related]
17. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study.
Imai Y; Chou T; Tobinai K; Tanosaki R; Morishima Y; Ogura M; Shimazaki C; Taniwaki M; Hiraoka A; Tanimoto M; Koike T; Kogawa K; Hirai H; Yoshida T; Tamura K; Kishi K; Hotta T;
Bone Marrow Transplant; 2005 Mar; 35(5):479-87. PubMed ID: 15654349
[TBL] [Abstract][Full Text] [Related]
18. Micrometastases in apheresis products predict shorter progression-free and overall survival in patients with breast cancer undergoing high-dose chemotherapy (HDCT) and autologous blood stem cell transplantation (ABSCT).
Syme R; Stewart D; Rodriguez-Galvez M; Luider J; Auer Y; Klassen J; Morris D; Brown C; Russell J; Glück S
Bone Marrow Transplant; 2003 Aug; 32(3):307-11. PubMed ID: 12858203
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
20. Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience.
Watanabe T; Kawano Y; Watanabe A; Takaue Y
Haematologica; 1999 Feb; 84(2):167-76. PubMed ID: 10091416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
